(Reuters) -Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the main ingredient in its popular ...

Novo Nordisk (NVO) files additional court cases against vendors selling cheaper semaglutide knockoffs. Read more here.

Novo Nordisk today announced the filing of 14 new lawsuits to safeguard patients from unsafe and unapproved compounded drugs ...

Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...

The online weight loss company launches a $119 starter plan using low-dose semaglutide and behavioral coaching to improve ...

Wegovy and Zepbound - except the weight regain is worse, because of the extreme way in which these medications suppress your ...

Eris Lifesciences is using its growing insulin business to position itself as a serious contender in India’s fast-expanding ...

A study published in Cell Metabolism looks at the effects of semaglutide on skeletal muscle mass in mice. Prof Lora Heisler, Director of Research, Rowett Institute, University of Aberdeen, Rowett ...

Russia is currently experiencing a boom in the sales of Ozempic (semaglutide) and its analogues due to a high demand for such drugs among domestic customers, reports The Pharma Letter’s local ...

New lawsuits target pharmacies producing compounded versions of semaglutide ‘under the fake guise of personalization,’ the Danish drugmaker said ...

Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of ...

Shares of telehealth firm Hims & Hers fell as much as 5% on Tuesday after the company reported weaker-than-expected second-quarter revenue, hurt by a loss of subscribers in its weight-loss treatment ...